Paid Clinical Trials Buffalo

Discover 622 paid clinical trials in Buffalo, New York. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.

Filter

Filter results

Results: 622

Anticoagulant ManagementPerioperative Anticoagulant Use for Surgery Evaluation -Virtual Visit (PAUSE-Virtual)

Recruiting

Sponsor:

McMaster University

Location:

Hamilton, Detroit MI, Ottawa, Philadelphia PAshow 3 more

Code:

NCT06844227

Conditions

Atrial Fibrillation (AF)

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

ICXP007Safety and Efficacy Study of ICXP007 With Compression Bandaging for the Treatment of Non-Infected Venous Leg Ulcers

Recruiting

PHASE3

Sponsor:

Intercytex

Location:

Welland, Oakville, Mississauga, Torontoshow 34 more

Code:

NCT00232973

Conditions

Leg Ulcer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

ICXP007

MarstacimabOpen-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors

Recruiting

PHASE3

Sponsor:

Pfizer

Location:

Hamilton, New Hyde Park NY, Iowa City IA, Edmontonshow 1 more

Code:

NCT05145127

Conditions

Hemophilia A

Hemophilia B

Eligibility Criteria

Sex: Male

Age: 1 - 70+

Healthy Volunteers: Not accepted

Interventions

PF-06741086

XL092 & NivolumabStudy of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma

Recruiting

PHASE3

Sponsor:

Exelixis

Location:

Buffalo NY, Cleveland OH, New York NY, Knoxville TNshow 6 more

Code:

NCT05678673

Conditions

Non-Clear Cell Renal Cell Carcinoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

XL092

Nivolumab

Sunitinib Malate

TezepelumabEfficacy and Safety of Tezepelumab in Patients With Eosinophilic Esophagitis

Recruiting

PHASE3

Sponsor:

AstraZeneca

Location:

Niagara Falls, Hamilton, London, Chesterfield MIshow 30 more

Code:

NCT05583227

Conditions

Eosinophilic Esophagitis

Eligibility Criteria

Sex: All

Age: 12 - 70+

Healthy Volunteers: Not accepted

Interventions

Tezepelumab

Placebo

MK-6070A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001)

Recruiting

PHASE1

PHASE2

Sponsor:

Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Location:

Buffalo NY, Cleveland OH, Detroit MI, New York NYshow 7 more

Code:

NCT04471727

Conditions

Small-Cell Lung Cancer

Neuroendocrine Carcinoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Gocatamig

Atezolizumab

Ifinatamab Deruxtecan (I-DXd)

Isolated Skin VasculitisA Randomized Multicenter Study for Isolated Skin Vasculitis

Recruiting

PHASE2

Sponsor:

University of Pennsylvania

Location:

Hamilton, Toronto, Cleveland OH, Hershey PAshow 11 more

Code:

NCT02939573

Conditions

Primary Cutaneous Vasculitis

Cutaneous Polyarteritis Nodosa

IgA Vasculitis

Henoch-Schönlein Purpura

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Colchicine

Dapsone

Azathioprine

Neratinib & PalbociclibTesting the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)

Recruiting

PHASE2

Sponsor:

National Cancer Institute (NCI)

Location:

Buffalo NY, Erie PA, Syracuse NY, Altoona PAshow 111 more

Code:

NCT06126276

Conditions

Malignant Female Reproductive System Neoplasm

Malignant Solid Neoplasm

Recurrent Malignant Female Reproductive System Neoplasm

Recurrent Malignant Solid Neoplasm

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Biopsy Procedure

Biospecimen Collection

Computed Tomography

Echocardiography Test

Magnetic Resonance Imaging

SurVaxMA Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma

Recruiting

PHASE1

Sponsor:

Pediatric Brain Tumor Consortium

Location:

Buffalo NY, Toronto, Pittsburgh PA, Washington DCshow 10 more

Code:

NCT04978727

Conditions

Medulloblastoma

Glioblastoma Multiforme

Anaplastic Astrocytoma

High-grade Astrocytoma NOS

Anaplastic Oligodendroglioma

Eligibility Criteria

Sex: All

Age: 1 - 21

Healthy Volunteers: Not accepted

Interventions

SurVaxM for patients with relapsed or progressive MB, HGG or ependymoma ages ≥10 and ≤21 years

SurVaxM for patients with relapsed or progressive MB, HGG or ependymoma ages ≥1 and <10 years

SurVaxM for patients with non-relapsed DIPG post radiation-therapy ages ≥1 and ≤21 years

IbrutinibA Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia

Recruiting

PHASE2

Sponsor:

Janssen Research & Development, LLC

Location:

St. Catharines, Flemington NJ, Florham Park NJ, Nyack NYshow 29 more

Code:

NCT05963074

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell

Small Lymphocytic Lymphoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Ibrutinib

Venetoclax